Literature DB >> 11283277

Clostridium botulinum type A haemagglutinin-positive progenitor toxin (HA(+)-PTX) binds to oligosaccharides containing Gal beta1-4GlcNAc through one subcomponent of haemagglutinin (HA1).

Kaoru Inoue1, Yukako Fujinaga1, Koichi Honke2, Hideyuki Arimitsu1, Nazira Mahmut1, Yoshihiko Sakaguchi1, Tohru Ohyama3, Toshihiro Watanabe3, Katsuhiro Inoue3, Keiji Oguma1.   

Abstract

Haemagglutinin (HA) activity of Clostridium botulinum type A 19S and 16S toxins (HA-positive progenitor toxin; HA(+)-PTX) was characterized. HA titres against human erythrocytes of HA(+)-PTX were inhibited by the addition of lactose, D-galactose, N-acetyl-D-galactosamine and D-fucose to the reaction mixtures. A direct glycolipid binding test demonstrated that type A HA(+)-PTX strongly bound to paragloboside and some neutral glycolipids, but did not bind to gangliosides. Type A HA(+)-PTX also bound to asialoglycoproteins (asialofetuin, neuraminidase-treated transferrin), but not to sialoglycoproteins (fetuin, transferrin). Although glycopeptidase F treatment of asialofetuin abolished the binding of HA(+)-PTX, endo-alpha-N-acetylgalactosaminidase treatment did not. Thus these results can be interpreted as indicating that type A HA(+)-PTX detects and binds to Gal beta 1-4GlcNAc in paragloboside and the N-linked oligosaccharides of glycoproteins. Regardless of neuraminidase treatment, type A HA(+)-PTX bound to glycophorin A which is a major sialoglycoprotein on the surface of erythrocytes. Both native glycophorin A and neuraminidase-treated glycophorin A inhibited the binding of erythrocytes to type A HA(+)-PTX. Since the N:-linked oligosaccharide of glycophorin A is di-branched and more than 50% of this sugar chain is monosialylated, type A HA(+)-PTX probably bound to the unsialylated branch of the N-linked oligosaccharide of glycophorin A and agglutinated erythrocytes. One subcomponent of HA, designated HA1, did not agglutinate native erythrocytes, although it did bind to erythrocytes, paragloboside and asialoglycoproteins in a manner quite similar to that of HA(+)-PTX. These results indicate that type A HA(+)-PTX binds to oligosaccharides through HA1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11283277     DOI: 10.1099/00221287-147-4-811

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  12 in total

1.  Purification of fully activated Clostridium botulinum serotype B toxin for treatment of patients with dystonia.

Authors:  Hideyuki Arimitsu; Kaoru Inoue; Yoshihiko Sakaguchi; Jaechul Lee; Yukako Fujinaga; Toshihiro Watanabe; Tohru Ohyama; Robert Hirst; Keiji Oguma
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

Review 2.  Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting.

Authors:  B R Singh
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

3.  Binding of Clostridium botulinum C3 exoenzyme to intact cells.

Authors:  Astrid Rohrbeck; Leonie von Elsner; Sandra Hagemann; Ingo Just
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-03-02       Impact factor: 3.000

Review 4.  Assembly and function of the botulinum neurotoxin progenitor complex.

Authors:  Shenyan Gu; Rongsheng Jin
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

Review 5.  Architecture of the botulinum neurotoxin complex: a molecular machine for protection and delivery.

Authors:  Kwok-Ho Lam; Rongsheng Jin
Journal:  Curr Opin Struct Biol       Date:  2015-04-15       Impact factor: 6.809

Review 6.  Glycosphingolipids-sweets for botulinum neurotoxin.

Authors:  Brian C Yowler; Cara-Lynne Schengrund
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

Review 7.  Interaction of botulinum toxin with the epithelial barrier.

Authors:  Yukako Fujinaga
Journal:  J Biomed Biotechnol       Date:  2010-02-14

8.  Cloning, expression, purification, and characterization of biologically active recombinant hemagglutinin-33, type A botulinum neurotoxin associated protein.

Authors:  Yu Zhou; Sowmya Paturi; Paul Lindo; Suzanne M Shoesmith; Bal Ram Singh
Journal:  Protein J       Date:  2007-01       Impact factor: 4.000

9.  Application of purified botulinum type a neurotoxin to treat experimental trigeminal neuropathy in rats and patients with urinary incontinence and prostatic hyperplasia.

Authors:  Yoshizo Matsuka; Teruhiko Yokoyama; Yumiko Yamamoto; Tomonori Suzuki; Ni Nengah Dwi Fatmawati; Atsushi Nishikawa; Tohru Ohyama; Toshihiro Watanabe; Takuo Kuboki; Atsushi Nagai; Keiji Oguma
Journal:  J Toxicol       Date:  2012-06-14

10.  Structure of a bimodular botulinum neurotoxin complex provides insights into its oral toxicity.

Authors:  Kwangkook Lee; Shenyan Gu; Lei Jin; Thi Tuc Nghi Le; Luisa W Cheng; Jasmin Strotmeier; Anna Magdalena Kruel; Guorui Yao; Kay Perry; Andreas Rummel; Rongsheng Jin
Journal:  PLoS Pathog       Date:  2013-10-10       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.